Inventor · disambiguated record
Jamie M. Orengo
Also filed as: ORENGO JAMIE · ORENGO JAMIE M
34 granted patents·16 pending applications·311 citations·filing 2013–2025
97Inventor score
Files withREGENERON PHARMA50
Top patents by PatentIndex Score
50 records- 0198US9637535B2IL-33 antagonists and uses thereofREGENERON PHARMA·Filed 2014·Granted May 2, 2017·36 cites·33 claims
- 0298US9453072B2Anti-IL-33 antibodiesREGENERON PHARMA·Filed 2014·Granted Sep 27, 2016·49 cites·20 claims
- 0398US9079948B2Human antibodies to Fel d1 and methods of use thereofREGENERON PHARMA·Filed 2013·Granted Jul 14, 2015·83 cites·12 claims
- 0497US10676530B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptorREGENERON PHARMA·Filed 2017·Granted Jun 9, 2020·14 cites·24 claims
- 0597US10669341B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an antibody to IL-4 receptorREGENERON PHARMA·Filed 2017·Granted Jun 2, 2020·13 cites·20 claims
- 0697US10392439B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitorREGENERON PHARMA·Filed 2014·Granted Aug 27, 2019·22 cites·11 claims
- 0796US10815305B2Methods of treating inflammatory conditionsREGENERON PHARMA·Filed 2017·Granted Oct 27, 2020·11 cites·44 claims
- 0895US11866503B2Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptorREGENERON PHARMA·Filed 2020·Granted Jan 9, 2024·3 cites·20 claims
- 0995US10011647B2IL-33 antagonists and uses thereofREGENERON PHARMA·Filed 2017·Granted Jul 3, 2018·8 cites·36 claims
- 1095US10000564B2Methods of treating an inflammatory condition or sensitivity to an allergen with anti-IL-33 antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 19, 2018·14 cites·38 claims
- 1193US10793624B2Human antibodies to Bet v 1 and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Oct 6, 2020·12 cites·18 claims
- 1292US11767358B2Human antibodies to Bet v 1 and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Sep 26, 2023·3 cites·40 claims
- 1392US11485788B2Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R inhibitorREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·2 cites·12 claims
- 1492US11174305B2Human antibodies to Fel d1 and methods of use thereofREGENERON PHARMA·Filed 2018·Granted Nov 16, 2021·4 cites·21 claims
- 1591US10519230B2Nucleic acids encoding IL-33 antibodiesREGENERON PHARMA·Filed 2018·Granted Dec 31, 2019·5 cites·20 claims
- 1691US10047153B2Human antibodies to Fel d1 and methods of use thereofREGENERON PHARMA·Filed 2017·Granted Aug 14, 2018·6 cites·32 claims
- 1790US10851158B2Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereofREGENERON PHARMA·Filed 2018·Granted Dec 1, 2020·4 cites·27 claims
- 1889US2024425580A1Anti-IL-33 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1988US11897945B2Methods of treating allergy using anti-Bet v 1 antibodiesREGENERON PHARMA·Filed 2021·Granted Feb 13, 2024·2 cites·37 claims
- 2087US10640558B2Anti-IL-25 antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted May 5, 2020·3 cites·18 claims
- 2185US9475869B2Human antibodies to fel d1 and methods of use thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·3 cites·17 claims
- 2284US11352417B2Method of treating an allergy with allergen-specific monoclonal antibodiesREGENERON PHARMA·Filed 2017·Granted Jun 7, 2022·2 cites·9 claims
- 2383US10935554B2Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)REGENERON PHARMA·Filed 2014·Granted Mar 2, 2021·3 cites·5 claims
- 2483US10047152B2Human antibodies to fel D1 and methods of use thereofREGENERON PHARMA·Filed 2016·Granted Aug 14, 2018·2 cites·8 claims
- 2582US10774128B2IL-33 antagonists and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 15, 2020·2 cites·20 claims
- 2681US11104729B2Anti-IL-33 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Aug 31, 2021·1 cites·18 claims
- 2781US2023159647A1Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2880US12252530B2Human antibodies to Fel d1 and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Mar 18, 2025·0 cites·32 claims
- 2980US12037388B2Anti-IL-33 antibodies and uses thereofREGENERON PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·26 claims
- 3079US11964016B2Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergyREGENERON PHARMA·Filed 2020·Granted Apr 23, 2024·1 cites·99 claims
- 3179US2024209102A1Methods of treating inflammatory conditionsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3278US9840557B2Anti-IL-25 antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Dec 12, 2017·2 cites·21 claims
- 3376US11578127B2Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereofREGENERON PHARMA·Filed 2019·Granted Feb 14, 2023·1 cites·17 claims
- 3476US2024083986A1Human antibodies to bet v 1 and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3573US12441797B2Anti-FC ϵ-R1 α (FCϵR1α) antibodies, bispecific antigen-binding molecules that bind FCϵR1α and CD3, and uses thereofREGENERON PHARMA·Filed 2023·Granted Oct 14, 2025·0 cites·14 claims
- 3672US2023279131A1Anti-il2 receptor gamma antigen-binding proteinsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3771US2024350625A1Combination of il-4/il-13 pathway inhibitors and plasma cell abalation for treating allergyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3870US2024092882A1Method of treating an allergy with allergen-specific monoclonal antibodiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3969US2023203141A1Methods of treating an allergy with allergen-specific monoclonal antibodiesREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4068US11542326B2Anti-IL-25 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Jan 3, 2023·0 cites·12 claims
- 4168US2021148929A1Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)REGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4264US11629195B2Anti-IL2 receptor gamma antigen-binding proteinsREGENERON PHARMA·Filed 2020·Granted Apr 18, 2023·0 cites·23 claims
- 4361US2022064270A1Method of treating an allergy with allergen-specific monoclonal antibodiesREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4459US2024350626A1Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonistREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4556US2023349919A1Methods Of Mapping Antigen Specificity To Antibody-Secreting CellsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4652US2022220211A1Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonistREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4750US10005834B2Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereofREGENERON PHARMA·Filed 2016·Granted Jun 26, 2018·0 cites·27 claims
- 4848US2025276092A1Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody responseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 4947US2025242018A1Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administrationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 5037US2025263471A1Methods of treating allergy using anti-bet v 1 antibodiesREGENERON PHARMA·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jamie M. Orengo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →